Division of Pediatric Infectious Diseases, Department of Pediatrics, Marmara University School of Medicine, Istanbul, Turkey.
Division of Pediatric Infectious Diseases, Department of Pediatrics, Marmara University School of Medicine, Istanbul, Turkey.
J Mycol Med. 2021 Mar;31(1):101082. doi: 10.1016/j.mycmed.2020.101082. Epub 2020 Nov 11.
Invasive candidiasis (IC) is a life-threatening fungal infection with high morbidity and mortality. In this study, we aimed to investigate the Candida species distribution and antifungal drug susceptibility and to identify the risk factors associated with IC mortality in children. We conducted a retrospective, single-centre study of paediatric IC in patients from a tertiary care hospital in Turkey between January 2013 and February 2019. A total of 56 Candida isolates underwent antifungal susceptibility testing performed by Sensititre YeastOne YO10 panel, and the demographic and clinical data of 65 patients were examined during the study period. The most commonly isolated species was Candida albicans in 30 patients (46%), followed by C. parapsilosis in 25 patients (38%) and C. tropicalis in three patients (5%). According to the antifungal drug susceptibility testing, C. albicans was fully susceptible to fluconazole and the other antifungal agents (100%). None of the isolates displayed resistance to anidulafungin, micafungin, flucytosine, posaconazole, voriconazole or itraconazole. There were low rates of resistance to fluconazole (1.8%), caspofungin (1.8%) and micafungin (1.8%). In addition, 5.3% of the Candida isolates were susceptible in a dose-dependent manner to itraconazole, 3.6% were susceptible to voriconazole and fluconazole and 1.8% were susceptible to anidulafungin. The mortality rate of IC was 15.4%. Thrombocytopenia after IC treatment was significantly associated with mortality in the multivariate analysis. These results, which help determine the species distribution, antifungal susceptibility patterns and risk factors for mortality, could make a significant contribution to the management of these challenging infections, including choosing appropriate empirical antifungal therapy.
侵袭性念珠菌病(IC)是一种危及生命的真菌感染,发病率和死亡率都很高。本研究旨在调查儿童念珠菌病的菌种分布和抗真菌药物敏感性,并确定与 IC 死亡率相关的危险因素。我们对土耳其一家三级护理医院的儿科 IC 患者进行了回顾性单中心研究,时间为 2013 年 1 月至 2019 年 2 月。共有 56 株念珠菌进行了抗真菌药敏试验,采用 Sensititre YeastOne YO10 板,研究期间检查了 65 例患者的人口统计学和临床数据。最常见的分离菌种是 30 例(46%)的白色念珠菌,其次是 25 例(38%)的近平滑念珠菌和 3 例(5%)的热带念珠菌。根据抗真菌药敏试验,白色念珠菌对氟康唑和其他抗真菌药物(100%)完全敏感。无分离株对安尼卡fungin、米卡芬净、氟胞嘧啶、泊沙康唑、伏立康唑或伊曲康唑耐药。氟康唑(1.8%)、卡泊芬净(1.8%)和米卡芬净(1.8%)耐药率较低。此外,5.3%的念珠菌分离株对伊曲康唑呈剂量依赖性敏感,3.6%对伏立康唑和氟康唑敏感,1.8%对安尼卡fungin敏感。IC 的死亡率为 15.4%。IC 治疗后血小板减少与多变量分析中的死亡率显著相关。这些结果有助于确定菌种分布、抗真菌药敏模式和死亡率的危险因素,对抗真菌经验治疗的选择具有重要意义。